#experimentation

wist@diasp.org

A quotation from Hazlitt, William

It is erroneous to tie down individual genius to ideal models. Each person should do that, not which is best in itself, even supposing this coudl be known, but that which he can do best, which he will find out if left to himself. Spenser could not have written Paradise Lost, nor Milton the Faerie Queene. Those who aim at faultless regularity will only produce mediocrity, and no one ever approaches perfection except by stealth, and unknown to themselves.

William Hazlitt (1778-1830) English writer
“Thoughts on Taste”, Edinburgh Magazine (1819-07)

#quote #quotes #quotation #art #artist #author #genius #creativity #creator #excellence #experimentation #ideal #individuality #mediocrity #perfection #standards #style #writing
Sourcing / notes: https://wist.info/hazlitt-william/67115/

tpq1980@iviv.hu

With regards to #medical #mandates, "#Vaccine passports" and/or "#lockdowns" in the #UK please see:

Sidaway v. Board of Governors of the Bethlem Royal Hospital and the Maudsley Hospital

"A mentally competent patient has an absolute right to refuse to #consent to medical #treatment, for any reason, #rational or #irrational, or for no #reason at all, even where that decision may lead to his or her own #death."

This establishes the #principle of a legal right to #refuse medical treatment, preventative or curative. The ruling has been used in many cases and upheld.

https://swarb.co.uk/sidaway-v-board-of-governors-of-the-bethlem-royal-hospital-and-the-maudsley-hospital-hl-21-feb-1985/

In addition, please see the #International #Covenant on Civil and #Political #Rights Article 1 Section 1, Article 7 and Article 12 Section 1. The UK signed the #ICCPR September 1968 and ratified it in May 1976.

ICCPR Article 1 Section 1:
"All peoples have the #right of self-determination. By #virtue of that right they freely determine their political status and freely pursue their #economic, #social and #cultural development."

ICCPR Article 7:
"No one shall be subjected to #torture or to #cruel, #inhuman or degrading #treatment or #punishment. In particular, no one shall be subjected without his #free #consent to medical or #scientific #experimentation."

ICCPR Article 12 Section 1:
"Everyone #lawfully within the #territory of a #State shall, within that territory, have the right to #liberty of movement and #freedom to choose his residence."

The UK is a ratified signatory nation of the ICCPR and has a #legal obligation to abide by the Articles within the treaty.

https://www.ohchr.org/en/professionalinterest/pages/ccpr.aspx

tpq1980@iviv.hu

With regards to #medical #mandates, "#Vaccine passports" &/or "#lockdowns" in the #USA please see:

14th Amendment, Section 1, Due Process Clause in conjunction with Washington v. Harper (1990) & Cruzan v. Director Missouri Department of #Health (1990).

14th Amendment, Section 1:
"All persons born or naturalized in the United States, and subject to the #jurisdiction thereof, are citizens of the United States and of the state wherein they reside. No state shall make or enforce any #law which shall abridge the privileges or immunities of #citizens of the United States; nor shall any state deprive any person of #life, #liberty, or #property, without due process of law; nor deny to any person within its jurisdiction the equal protection of the laws."

https://www.law.cornell.edu/constitution/amendmentxiv
https://constitutioncenter.org/interactive-constitution/interpretation/amendment-xiv/clauses/701

Washington v. Harper (1990)
"The forcible #injection of medication into a nonconsenting person's body represents a substantial interference with that person's #liberty."

https://en.wikipedia.org/wiki/Washington_v._Harper
https://supreme.justia.com/cases/federal/us/494/210/

Cruzan v. Director, Missouri Department of Health (1990)
"[a competent person has a] constitutionally protected liberty interest in refusing unwanted medical treatment."

https://en.wikipedia.org/wiki/Cruzan_v._Director,_Missouri_Department_of_Health
https://supreme.justia.com/cases/federal/us/497/261/

Article 6 of the US Constitution in conjunction with The International Covenant on Civil & Political Rights Article 1 Section 1, Article 7 & Article 12 Section 1. The USA signed the #ICCPR October 1977 & #ratified it in June 1992.

US #Constitution, Article 6:
"...all #Treaties made, or which shall be made, under the #Authority of the United States, shall be the supreme Law of the Land; and the #Judges in every State shall be bound thereby..."

https://constitution.congress.gov/constitution/article-6/

ICCPR Article 1 Section 1:
"All peoples have the #right of self-determination. By #virtue of that right they freely determine their #political status and freely pursue their #economic, #social & #cultural development."

ICCPR Article 7:
"No one shall be subjected to #torture or to #cruel, #inhuman or degrading #treatment or #punishment. In particular, no one shall be subjected without his free #consent to #medical or #scientific #experimentation."

ICCPR Article 12 Section 1:
"Everyone #lawfully within the #territory of a #State shall, within that territory, have the right to liberty of movement and #freedom to choose his residence."

The USA is a ratified signatory #nation of the ICCPR and has a #legal obligation to abide by the Articles within the #treaty.

https://www.ohchr.org/en/professionalinterest/pages/ccpr.aspx

hylascall@nerdpol.ch

Game gets easier and easier

#covid #vaccines #experimentation #antibodies #effectiness #misleading-data

"Dopo Pfizer che ha pubblicato i dati a sei mesi del proprio vaccino, ricavandoli con apprezzabile impegno da quanto ancora il suo originario studio clinico ora in disarmo era in grado di dire, arriva Moderna che sulla prestigiosa rivista Science propone un approccio radicalmente differente e alquanto originale per i suoi dati a sei mesi.
I dati pubblicati infatti non riguardano più l'efficacia dei vaccini sullo sviluppo di covid o su altri aspetti di diretto rilievo clinico, bensì la persistenza in circolo di anticorpi contro le diverse varianti del virus.
Dal punto di vista aziendale l'approccio è molto conveniente in quanto permette di evitare di condurre studi su decine di migliaia di persone, come uno studio di efficacia clinica imporrebbe. Nel presente lavoro tutte le analisi sono state condotte su 24 persone, 8 per fascia d'età. L'idea alla base dello studio è ovviamente che la presenza di anticorpi sia predittiva di una determinata protezione.
A oggi tuttavia non vi è alcuna evidenza che un determinato profilo anticorpale possa avere un qualsivoglia significati rispetto ai rischi del covid. Coerentemente, la presenza di anticorpi in un qualsiasi individuo è considerata indicazione di un passato covid o di una passata vaccinazione, ma non esistono livelli qualitativi o quantitativi utili a riconoscere l'esistenza di una protezione. E probabilmente non esisteranno mai.
In altri termini, mentre dal punto di vista dell'industria vedersi riconoscere la validità della presenza di anticorpi come surrogato della protezione contro il covid rappresenta un'attraente prospettiva che le semplificherebbe enormemente la vita per questi come per futuri vaccini, dal punto di vista dei sistemi sanitari e dei cittadini un dato del genere non sposta di nulla "gli equilibri", poichè quello che serve in concreto per comprendere se e quanto un vaccino possa essere utile è documentarne la capacità di ridurre contagi, malattie, ricoveri e decessi.
Ma per ottenere queste informazioni sono indispensabili quegli studi difficili, lungi e costosi che tutte le aziende si sono affrettate ad abbandonare (con le migliori motivazioni etiche) una volta incassate le autorizzazioni in emergenza. E non bastano certo le affannose raccolte di dati osservazionali dal mondo reale che le istituzioni si affannano a condurre.
Così, il riscontro di tassi anticorpali apprezzabili in un paio di dozzine di persone sono al massimo delle belle lucciole che brillano nel cielo notturno di un'autorevolissima rivista scientifica, ma per uscire dal buio del tunnel servono come minimo delle potenti lanterne, che solo studi clinici ben progettati e appropriatamente condotti ci potranno fornire. E se si continua a insistere su una sola strategia monocorde non è nemmeno detto che bastino. "

Dott. Marco Cosentino

"After Pfizer, which has published the data of six months of its vaccine, obtained with appreciable effort from what its original clinical study now in disarmament was still able to say, comes Moderna in the prestigious journal Science proposes a radically different approach and quite original for its data to six months.
The published data no longer concern the effectiveness of vaccines on the development of covid or on other aspects of direct clinical importance, but the persistence in circulation of antibodies against the different variants of the virus.
From a business point of view the approach is very convenient as it allows you to avoid conducting studies on tens of thousands of people, as a clinical efficacy study would require. In the present study, all analyses were conducted on 24 people, 8 by age group. The idea behind the study is obviously that the presence of antibodies is predictive of a certain protection.
To date, however, there is no evidence that a given antibody profile can have any significance in relation to the risks of covid. Consistently, the presence of antibodies in any individual is considered an indication of a past covid or a past vaccination, but there are no qualitative or quantitative levels useful to recognize the existence of protection. And they probably never exist.
In other words, while from the point of view of the industry to be recognized the validity of the presence of antibodies as a surrogate of protection against the covid represents an attractive perspective that would simplify greatly the life for these as for future vaccines, from the point of view of health systems and of the citizens of a given gender not move anything "the balance", as the one who serves in practice to understand if and how a vaccine might be useful is to document the ability to reduce infections, illnesses, hospitalizations, and deaths.
But to obtain this information are indispensable those difficult, long and expensive studies that all companies have rushed to abandon (with the best ethical reasons) once they have collected emergency authorizations. And the hard-working collections of observational data from the real world that institutions are struggling to conduct are certainly not enough.
Thus, the finding of appreciable antibody rates in a couple of dozen people are at most beautiful fireflies shining in the night sky of a very authoritative scientific journal, but to get out of the darkness of the tunnel serve as a minimum of powerful lanterns, which only well-designed and properly conducted clinical studies will be able to provide us with. And if we continue to insist on a single one-way strategy, it is not even said that they will suffice. Dr. Marco Cosentino

Marco Cosentino, PhD in Pharmacology and Toxicology, as well as full professor of Pharmacology at the School of Medicine of the University of Insubria, where he directs the Research Center in Medical Pharmacology. Professor Cosentino is also the author of hundreds of publications in international journals, books and book chapters, concerning the pathophysiology and pharmacotherapy of diseases of the nervous and immune systems, clinical pharmacology, pharmacogenetics and pharmacovigilance.

bastamedia@framasphere.org